{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"36","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"The primary endpoint was 2-year cumulative incidence of relapse/progression (RP), defined as time from alloHCT to disease recurrence or progression. Cumulative incidences for RP was generated in a competing-risk setting, given that death events were competing events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.\n\nrituximab: Given IV fludarabine phosphate: Given IV melphalan: Given IV sirolimus: Given PO tacrolimus: Given PO or IV allogeneic hematopoietic stem cell transplantation: Undergo APBSCT indium In 111 ibritumomab tiuxetan: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV","id":"OG000","title":"0.4 mCi 90Y-Ibritumomab Tiuxetan"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From the initial treatment to the last disease assessment, up to two years","title":"Relapse/Progression Rate at Two Years","type":"PRIMARY","unitOfMeasure":"percentage of cumulative incidence"}